# Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

> **NCT04289779** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Deepak Kilari** · enrollment: 46 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Atezolizumab
- **PROCEDURE:** Cystectomy

## Key facts

- **NCT ID:** NCT04289779
- **Lead sponsor:** Deepak Kilari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-21
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289779, "Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04289779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*